REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/05/2026
Voltar para busca
Dado oficial do USPTO
MEZZION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
05/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 41, 42, 44
Data de depósito
08/11/2018
Data de registro
04/05/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/05/2021
Última transação
05/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
3
Tipo de titular
99
Localização do titular
Seoul, KR
Examinador
MARTIN, CHRISTINE C
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The word "MEZZION" with the "O" replaced with an open ended heart with a stylized image of a person therein closing the heart shape.
Titulares e representantes
Titulares
Mezzion Pharma Co., Ltd.
Representantes
Daniel R. Mello Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Classificação técnica
Classes Nice
Classe 5Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of diseases and disordersPharmaceutical preparations for the treatment of cardiac diseases and disorders; Pharmaceutical preparations for the treatment of cardiac diseases and disorderssingle ventricle heart disease (SVHD)including SVHD subjects who have undergone Fontan Palliation; medicinal preparations for cardiac diseasesingle ventricle heart disease (SVHD); pharmaceuticalsdrugs for the treatment of cardiac diseasesingle ventricle heart disease (SVHD)including SVHD subjects who have undergone Fontan Palliation
Classe 41
Educational servicesseminars in the field of pharmaceuticalsmedicinehealthwellbeingcardiac issues and distribution of course materials in connection therewith; providing a website featuring blogs in the field of pharmaceuticalsmedicinehealthwellbeingcardiac issues
Classe 42
Medical and pharmaceutical research for the treatment of cardiac disease and disorderssingle ventricle heart disease (SVHD)including SVHD subjects who have undergone Fontan Palliation and product development services; scientific and technological research services related theretoscientific research services for the treatment of cardiac disease and disorderssingle ventricle heart disease (SVHD)including SVHD subjects who have undergone Fontan Palliation; medical testing servicesproviding medical testing services and information in the field of the treatment of cardiac disease and disorder researchsingle ventricle heart disease (SVHD) researchincluding SVHD subjects who have undergone Fontan Palliation for medical research purposes; conducting clinical trials for others; providing a website featuring medical and scientific research information in the field of pharmaceuticals and medicine
Classe 44
Providing websites featuring information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals and medicinehealthwellnesscardiac health issues; Medical testing and screening servicesmedical diagnostic testing services and medical screening the treatment of cardiac disease and disorderssingle ventricle heart disease (SVHD)including SVHD subjects who have undergone Fontan Palliation; providing a website featuring information in the field of health and wellness; providing a website featuring medical information in the field of cardiac issues; medical testing servicesproviding medical testing services and information in the field of the treatment of cardiac disease and disorderssingle ventricle heart disease (SVHD)including SVHD subjects who have undergone Fontan Palliation for diagnostic or treatment purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/08/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
23/08/2024
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
23/08/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/08/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/08/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/05/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
29/05/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/05/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/05/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/05/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/02/2021
PUBO
PUBLISHED FOR OPPOSITION
16/02/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/01/2021
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
14/01/2021
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
08/01/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/12/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/12/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/12/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/07/2020
GNRT
NON-FINAL ACTION E-MAILED
02/07/2020
CNRT
NON-FINAL ACTION WRITTEN
02/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/07/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
25/06/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
10/02/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
10/02/2020
CNSI
SUSPENSION INQUIRY WRITTEN
10/02/2020
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
10/02/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/08/2019
GNSL
LETTER OF SUSPENSION E-MAILED
02/08/2019
CNSL
SUSPENSION LETTER WRITTEN
02/08/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/07/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/07/2019
ALIE
ASSIGNED TO LIE
29/07/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/07/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/01/2019
GNRT
NON-FINAL ACTION E-MAILED
24/01/2019
CNRT
NON-FINAL ACTION WRITTEN
24/01/2019
DOCK
ASSIGNED TO EXAMINER
22/01/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
28/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/11/2018
NWAP
NEW APPLICATION ENTERED
12/11/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MEZZION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.